On Wednesday, ZIOPHARM Oncology Inc (NASDAQ:ZIOP)’s shares declined -0.95% to $11.53.
Formerly on March 30, ZIOPHARM Oncology Inc. and Intrexon Corporation (XON) declared their oncology programs will be strengthened through Intrexon’s new global partnership focused exclusively on novel chimeric antigen receptor T-cell (CAR-T) products with Merck Serono, the biopharmaceutical division of Merck KGaA, Darmstadt, Germany. Intrexon will share the economic provisions of this collaboration, counting upfront payment, milestones and royalties, equally with ZIOPHARM.
Under the partnership Merck Serono will elect CAR-T targets, two initially, for which it will provide certain research funding. Through its contract with Intrexon, ZIOPHARM will be responsible for any additional research and development expenditures. Once these candidates reach investigational new drug (IND) stage, the programs will be transferred to Merck Serono for clinical development and commercialization. ZIOPHARM and Intrexon will also independently conduct research and development on other CAR-T candidates, with Merck having the opportunity during clinical development to opt-in. ZIOPHARM’s other oncology programs will continue through its Exclusive Channel Partnership(ECC) with Intrexon.
“Controlled CAR-T treatments hold the promise of delivering the powerful benefit of a targeted immune response to cancer with the ability to modulate immune toxicity, leading to safer, more efficacious treatments,” said Jonathan Lewis, M.D., Ph.D., Chief Executive Officer of ZIOPHARM. “The partnershipwith Merck Serono brings world-class resources to our development efforts that greatly enhance our ability to translate CAR-T therapies from bench to bedside.”
ZIOPHARM Oncology, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing cancer therapies. The company is employing novel gene expression, and control and cells technologies to deliver cell-based therapies for the treatment of cancer.
Bristol-Myers Squibb Co (NYSE:BMY)’s shares dropped -0.94% to $63.43, during the last trading session on Wednesday.
On April 8, Bristol-Myers Squibb Co declared that it has accomplished the formerly declared planned acquisition of Flexus Biosciences, Inc.
The transaction comprises full rights to F001287, Flexus’ lead preclinical, small-molecule IDO1-inhibitor targeted for IND filing in the second half of 2015 and an IDO/TDO discovery program that comprises its IDO-selective, IDO/TDO dual and TDO-selective compound libraries. A newly formed entity established by the current shareholders of Flexus will retain, from and after the closing, all non-IDO/TDO assets of Flexus counting those related to Flexus’ Phase 1 FLT3 and CDK4/6 inhibitor, its earlier stage small-molecule Treg cancer immunotherapy programs, and its current personnel and facilities.
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It provides chemically-synthesized drugs or small molecules, and biologics in various therapeutic areas, counting virology comprising human immunodeficiency virus infection (HIV); oncology; neuroscience; immunoscience; and cardiovascular.
At the end of Wednesday’s trade, DDR Corp (NYSE:DDR)‘s shares dipped -0.93% to $18.06.
On April 1, DDR Corp (DDR), declared that it closed on the acquisition of one shopping center valued at $49 million and the disposition of 31 assets totaling $353 million at 100% ownership, or $153 million at the Company’s share, during the first quarter of 2015.
Comprised of in the total transactional activity for the quarter is the final dissolution of the Company’s joint venture with Coventry Real Estate Advisors (“Coventry”). DDR transferred to Coventry its 20% interest in 21 of the joint venture’s remaining 22-asset portfolio, valued at $49 million at the Company’s share, and concurrently eliminated the Company’s $36 million of pro rata joint venture debt. DDR had no GAAP economic interest in 18 of the 22 assets at the time of dissolution. In exchange for its interest in the portfolio, Coventry transferred to DDR its 80% interest in Buena Park Place, a 223,000-square-foot power center located in Orange County, California, valued at $39 million, and concurrently stepped down $26 million of debt that was secured by the asset. In accordance with the transaction, all charges in the associated lawsuits have been dismissed.
In addition to the dissolution of DDR’s former joint venture with Coventry, the Company also sold 10 assets totaling $104 million at the Company’s share. DDR is under contract to sell an additional seven assets totaling $80 million at the Company’s share.
DDR Corp. is an equity real estate investment trust. It invests in the real estate markets of the United States and Puerto Rico. The firm is in the business of acquiring, owning, developing, redeveloping, expanding, leasing and managing shopping centers. It formerly known as Developers Diversified Realty Corp. DDR Corp is based in Beachwood, Ohio.
Ventas, Inc (NYSE:VTR), ended its Wednesday’s trading session with -0.92% loss, and closed at $73.17.
On April 8, Ventas, Inc (VTR), declared that it will issue its first quarter 2015 earnings release preceding to the opening of trading on the New York Stock Exchange on Friday, April 24, 2015. A conference call to talk about those earnings will be held the same day at 10:00 a.m. Eastern Time (9:00 a.m. Central Time).
Ventas, Inc. is a publicly owned real estate investment trust. The firm engages in investment, administration, financing, and leasing of properties in the healthcare industry. It invests in the real estate markets of the United States and Canada. The firm primarily invests in healthcare-related facilities counting hospitals, skilled nursing facilities, senior housing facilities, medical office buildings, and other healthcare related facilities.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
